>>Signaling Pathways>> Proteases>> Acyltransferase>>Lecimibide

Lecimibide

Catalog No.GC71495

Lecimibide (Dup 128) 는 고지혈증 연구에 사용되는 강력하고 특이한 아세틸 보조효소 a: 콜레스테롤 아세틸 전이효소(ACAT) 억제제입니다.

Products are for research use only. Not for human use. We do not sell to patients.

Lecimibide Chemical Structure

Cas No.: 130804-35-2

Size 가격 재고 수량
1 mg
US$152.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents
Lecimibide (DuP 128) is a potent and specific acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor for antihyperlipidemia research.

Lecimibide (DuP 128)(10 μM, 24 h) can inhibit 85% of the cellular esterification reaction in HepG2 cells[1].

Lecimibide (DuP 128) (i.v., 2.2 mg/kg/day) significantly reduces total plasma triglyceride and very low-density lipoprotein (VLDL) triglyceride concentrations in pigs fed high fat and cholesterol levels, respectively 36% and 31%. There are no significant effects on total cholesterol, VLDL cholesterol, LDL cholesterol, HDL cholesterol, or LDL apoB concentrations[2].

References:
[1]. L J Wilcox, et al. Secretion of hepatocyte apoB is inhibited by the flavonoids, naringenin and hesperetin, via reduced activity and expression of ACAT2 and MTP. J Lipid Res. 2001 May;42(5):725-34.
[2]. J R Burnett, et al. Inhibition of cholesterol esterification by DuP 128 decreases hepatic apolipoprotein B secretion in vivo: effect of dietary fat and cholesterol. Biochim Biophys Acta. 1998 Jul 31;1393(1):63-79.

리뷰

Review for Lecimibide

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Lecimibide

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.